Table 3 Baseline characteristics of participants in respective trials continued (N/a- data not available).
Author | Duration of heel pain Median (SD and/or range) months | Base line morning pain VAS score (SD) | ||
|---|---|---|---|---|
| Â | Treatment group | Control group | Treatment Group | Control group |
Abt et al [21] | 19.0 | 19.0 | 5.7 | 5.3 |
Buch et al [27] | 20.7 (21.1, 6–120) | 24.0 (21.1,6–99) | 7.7 (1.4) | 7.7 (1.5) |
Buchbinder et al [10] | 9.0 (2–150) | 10.8 (2–222.5) | 7.3 (2.5) | 6.8 (3.2) |
Cosentino et al [33] | 8.2(6–12) | 8.2(1.2) | N/a | N/a |
Haake et al [11] | 13.0 (10–24) | 13.0 (9–24) | 7.8 (2.4) | 7.7 (2.3) |
Krischek et al [22] | 22.0 | 23.0 | N/a | N/a |
Ogden et al [28] | 32.2 | 35.9 | 8.1 | 8.2 |
Rompe et al [32] | 8.0 (6–19) | 10.0 (6–20) | N/a | N/a |
Rompe et al [30] | 16.0 (12–36) | 22.0 (12–38) | N/a | N/a |
Rompe et al [31] | 20.0 (12–60) | 18.0 (12–72) | 6.9 (1.3) | 7.0 (1.3) |
Speed et al [12] | 16.7 (12–312) | 13.5 (12–312) | 7.4(2.0) | 7.0(2.0) |